PCSA Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Processa Pharmaceuticals, Inc.'s net margin of 16.99%. Processa Pharmaceuticals, Inc.'s return on equity of -309.65% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Processa Pharmaceuticals, Inc. has a consensus price target of $1.00, signalling upside risk potential of 1090.48%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 35.94%. Given that Processa Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Processa Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Processa Pharmaceuticals, Inc. has a beta of 1.140, which suggesting that the stock is 13.98% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Processa Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Processa Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Processa Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Processa Pharmaceuticals, Inc.'s net income of -$3.4M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Processa Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 148.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Processa Pharmaceuticals, Inc. is -- versus 12.08x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kodiak Sciences, Inc. has a net margin of -- compared to Processa Pharmaceuticals, Inc.'s net margin of --. Processa Pharmaceuticals, Inc.'s return on equity of -309.65% beat Kodiak Sciences, Inc.'s return on equity of -201.8%.

Processa Pharmaceuticals, Inc. has a consensus price target of $1.00, signalling upside risk potential of 1090.48%. On the other hand Kodiak Sciences, Inc. has an analysts' consensus of $35.50 which suggests that it could grow by 40.43%. Given that Processa Pharmaceuticals, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Processa Pharmaceuticals, Inc. is more attractive than Kodiak Sciences, Inc..

Processa Pharmaceuticals, Inc. has a beta of 1.140, which suggesting that the stock is 13.98% more volatile than S&P 500. In comparison Kodiak Sciences, Inc. has a beta of 2.640, suggesting its more volatile than the S&P 500 by 164.038%.

Processa Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kodiak Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Processa Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Kodiak Sciences, Inc. pays out -- of its earnings as a dividend.

Processa Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Kodiak Sciences, Inc. quarterly revenues of --. Processa Pharmaceuticals, Inc.'s net income of -$3.4M is higher than Kodiak Sciences, Inc.'s net income of -$61.5M. Notably, Processa Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Kodiak Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Processa Pharmaceuticals, Inc. is -- versus -- for Kodiak Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pyxis Oncology, Inc. has a net margin of -- compared to Processa Pharmaceuticals, Inc.'s net margin of -650.85%. Processa Pharmaceuticals, Inc.'s return on equity of -309.65% beat Pyxis Oncology, Inc.'s return on equity of -90.91%.

Processa Pharmaceuticals, Inc. has a consensus price target of $1.00, signalling upside risk potential of 1090.48%. On the other hand Pyxis Oncology, Inc. has an analysts' consensus of $6.93 which suggests that it could grow by 387.68%. Given that Processa Pharmaceuticals, Inc. has higher upside potential than Pyxis Oncology, Inc., analysts believe Processa Pharmaceuticals, Inc. is more attractive than Pyxis Oncology, Inc..

Processa Pharmaceuticals, Inc. has a beta of 1.140, which suggesting that the stock is 13.98% more volatile than S&P 500. In comparison Pyxis Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Processa Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Processa Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pyxis Oncology, Inc. pays out -- of its earnings as a dividend.

Processa Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Pyxis Oncology, Inc. quarterly revenues of --. Processa Pharmaceuticals, Inc.'s net income of -$3.4M is higher than Pyxis Oncology, Inc.'s net income of -$22M. Notably, Processa Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pyxis Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Processa Pharmaceuticals, Inc. is -- versus 30.86x for Pyxis Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -- compared to Processa Pharmaceuticals, Inc.'s net margin of --. Processa Pharmaceuticals, Inc.'s return on equity of -309.65% beat Savara, Inc.'s return on equity of -78.83%.

Processa Pharmaceuticals, Inc. has a consensus price target of $1.00, signalling upside risk potential of 1090.48%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 95.52%. Given that Processa Pharmaceuticals, Inc. has higher upside potential than Savara, Inc., analysts believe Processa Pharmaceuticals, Inc. is more attractive than Savara, Inc..

Processa Pharmaceuticals, Inc. has a beta of 1.140, which suggesting that the stock is 13.98% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.

Processa Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Processa Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

Processa Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Processa Pharmaceuticals, Inc.'s net income of -$3.4M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Processa Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Processa Pharmaceuticals, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.